Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack
Sanplatec is leading the industry in the field of containers and devices for cell culture and live transport
These findings help explain how relapse-triggering memories can persist alongside those that support recovery
While many cases are treatable, a subset can become highly aggressive, spreading to distant organs and resisting conventional therapies
Genome editing holds extraordinary promise for treating previously incurable genetic diseases
he innovation could pave the way for early and low-cost screening of smoking exposure and second-hand smoke biomarkers
The 12-month alpha-testing phase will bring together ZEISS R&D, three academic collaborators, and three pharmaceutical industry partners
BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study
Subscribe To Our Newsletter & Stay Updated
